We are live on ! Find out more
XBIOW

Xenetic Biosciences, Inc. Warrants

Delisted

XBIOW was delisted on the 16th of July, 2024.

1 hedge funds and large institutions have $297K invested in Xenetic Biosciences, Inc. Warrants in 2019 Q4 according to their latest regulatory filings, with 0 funds opening new positions, increasing their positions, 1 reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

15% more capital invested

Capital invested by funds: $258K → $297K (+$39K)

0% more funds holding

Funds holding: 11 (0)

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 1

Holders
1
Holders Change
Holders Change %
0%
% of All Funds
0.02%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
Increased
Reduced
1
Closed
Calls
Puts
Net Calls
Net Calls Change

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
SM
Sabby Management
Florida
-$65.7K
Name Holding Trade Value Shares
Change
Change in
Stake
SM
1
Sabby Management
Florida
$297K -$65.7K -50,000 -19%

XBIOW Hedge Fund Activity: Q4 2019 in Review

1 of the 5,076 institutional investors tracked by Wall St. Rank reported a position in Xenetic Biosciences, Inc. Warrants (XBIOW) for Q4 2019, worth a combined $297K — up 15% from $258K a quarter earlier.

Fund positioning in XBIOW was balanced in Q4 2019: 0 funds opened new positions, 0 closed out, 0 added to existing stakes and 1 trimmed.

The largest seller was Sabby Management, cutting an estimated $65.7K.

  • 1 institutional investor held Xenetic Biosciences, Inc. Warrants (XBIOW) as of Q4 2019, unchanged from Q3 2019.
  • Funds reported $297K of Xenetic Biosciences, Inc. Warrants stock for Q4 2019, up 15% quarter-over-quarter.
  • 0 funds opened new Xenetic Biosciences, Inc. Warrants positions in Q4 2019 and 0 closed out.
  • The largest Xenetic Biosciences, Inc. Warrants seller in Q4 2019 was Sabby Management, an estimated $65.7K sold.

Based on aggregated 13F filings for Q4 2019.